23andMe Holding Co. (ME) PB Ratio: 0.51
Is 23andMe Holding Co.’s P/B ratio high or low?
23andMe Holding Co.'s P/B ratio of 0.51 is 69% below its 5-year average of 1.62, near the low end of its 5-year range (0.22–8.13).
2.66% above its 12-month average of 0.50.
ME PB Ratio Chart
ME Average PB Ratio Chart
ME Current vs Average PB Ratio Chart
ME PB Ratio Metrics
PB RATIO
0.51
PB RATIO AVG TTM
0.50
PB RATIO AVG 3Y
0.88
PB RATIO AVG 5Y
1.11
PB RATIO AVG 10Y
N/A
PB RATIO AVG 15Y
N/A
PB RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+2.66%
CURRENT VS 3Y AVG
-41.87%
CURRENT VS 5Y AVG
-54.02%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
ME Competitors' PB Ratio
| NAME | MARKET CAP | PB RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 23andMe Holding Co. (ME) | $15.31M | 0.51 | 0.50 | 0.88 | 1.11 |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.02B | 1.53 | 1.56 | 1.74 | 1.89 |
| Hims & Hers Health, Inc. (HIMS)vs › | $5.98B | 13.73 | 16.83 | 13.09 | 9.59 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.73B | 1.13 | 1.11 | 1.14 | 1.29 |
| Tempus AI, Inc. (TEM)vs › | $8.35B | 20.55 | 28.90 | 69.38 | 69.38 |
| Charles River Laboratories International, Inc. (CRL)vs › | $9.03B | 3.12 | 2.64 | 2.83 | 4.01 |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 1.44 | 1.00 | 0.99 | 1.29 |
| Baxter International Inc. (BAX)vs › | $10.77B | 1.78 | 1.60 | 2.25 | 3.04 |
| Align Technology, Inc. (ALGN)vs › | $12.52B | 3.02 | 2.97 | 4.41 | 6.30 |
| The Cooper Companies, Inc. (COO)vs › | $13.24B | 1.61 | 1.74 | 2.16 | 2.35 |
P/B vs. its own history
At 0.51, P/B is cheaper than usual, sitting higher than 3% of its 5-year history.
5-year low
0.22
median
1.18
5-year high
8.13
Book Value Analysis
P/B Ratio
0.51
Market Price / Book Value per Share
23andMe Holding Co. PB Ratio Formula & Definition
PB Ratio = Market Cap / Total Shareholders' Equity
The price-to-book ratio compares market capitalization to book value (shareholders' equity). Lower values can indicate a cheaper valuation relative to net assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
23andMe Holding Co. PB Ratio FAQ
- What is the P/B ratio for 23andMe Holding Co. (ME)?
- The P/B ratio for ME stock is 0.51.
- Is 23andMe Holding Co.'s P/B ratio high or low?
- 23andMe Holding Co.'s P/B ratio of 0.51 is 69% below its 5-year average of 1.62, near the low end of its 5-year range (0.22–8.13).
- What is the TTM average P/B ratio for 23andMe Holding Co. (ME)?
- The TTM average P/B ratio for ME stock is 0.50.
- What is the 3Y average P/B ratio for 23andMe Holding Co. (ME)?
- The 3Y average P/B ratio for ME stock is 0.88.
- What is the 5Y average P/B ratio for 23andMe Holding Co. (ME)?
- The 5Y average P/B ratio for ME stock is 1.11.
23andMe Holding Co. PB Ratio History
| DATE | PB RATIO |
|---|---|
| 2026-03-19 | 0.51 |
| 2026-03-09 | 0.51 |
| 2026-03-02 | 0.51 |
| 2026-02-10 | 0.51 |
| 2026-01-30 | 0.51 |
| 2025-11-25 | 0.51 |
| 2025-04-28 | 0.66 |
| 2025-04-25 | 0.61 |
| 2025-04-24 | 0.59 |
| 2025-04-23 | 0.55 |
| 2025-04-22 | 0.53 |
| 2025-04-21 | 0.54 |
| 2025-04-17 | 0.55 |
| 2025-04-16 | 0.54 |
| 2025-04-15 | 0.53 |
| 2025-04-14 | 0.53 |
| 2025-04-11 | 0.48 |
| 2025-04-10 | 0.49 |
| 2025-04-09 | 0.44 |
| 2025-04-08 | 0.51 |
| 2025-04-07 | 0.51 |
| 2025-04-04 | 0.55 |
| 2025-04-03 | 0.44 |
| 2025-04-02 | 0.52 |
| 2025-04-01 | 0.34 |
| 2025-03-31 | 0.31 |
| 2025-03-28 | 0.25 |
| 2025-03-27 | 0.32 |
| 2025-03-26 | 0.22 |
| 2025-03-25 | 0.27 |
| 2025-03-24 | 0.31 |
| 2025-03-21 | 0.75 |
| 2025-03-20 | 0.74 |
| 2025-03-19 | 0.77 |
| 2025-03-18 | 0.80 |
| 2025-03-17 | 0.84 |
| 2025-03-14 | 0.81 |
| 2025-03-13 | 0.76 |
| 2025-03-12 | 0.74 |
| 2025-03-11 | 0.66 |
| 2025-03-10 | 0.63 |
| 2025-03-07 | 0.63 |
| 2025-03-06 | 0.63 |
| 2025-03-05 | 0.63 |
| 2025-03-04 | 0.58 |
| 2025-03-03 | 0.62 |
| 2025-02-28 | 0.92 |
| 2025-02-27 | 0.92 |
| 2025-02-26 | 0.94 |
| 2025-02-25 | 0.94 |
| 2025-02-24 | 0.97 |
| 2025-02-21 | 1.02 |
| 2025-02-20 | 1.15 |
| 2025-02-19 | 1.14 |
| 2025-02-18 | 1.18 |
| 2025-02-14 | 1.07 |
| 2025-02-13 | 1.04 |
| 2025-02-12 | 1.04 |
| 2025-02-11 | 1.05 |
| 2025-02-10 | 1.08 |
| 2025-02-07 | 1.06 |
| 2025-02-06 | 1.09 |
| 2025-02-05 | 0.66 |
| 2025-02-04 | 0.69 |
| 2025-02-03 | 0.72 |
| 2025-01-31 | 0.78 |
| 2025-01-30 | 0.85 |
| 2025-01-29 | 0.86 |
| 2025-01-28 | 0.85 |
| 2025-01-27 | 0.84 |
| 2025-01-24 | 0.88 |
| 2025-01-23 | 0.88 |
| 2025-01-22 | 0.88 |
| 2025-01-21 | 0.90 |
| 2025-01-17 | 0.90 |
| 2025-01-16 | 0.90 |
| 2025-01-15 | 0.85 |
| 2025-01-14 | 0.85 |
| 2025-01-13 | 0.91 |
| 2025-01-10 | 0.96 |
| 2025-01-08 | 1.01 |
| 2025-01-07 | 0.99 |
| 2025-01-06 | 0.95 |
| 2025-01-03 | 0.95 |
| 2025-01-02 | 0.89 |
| 2024-12-31 | 0.81 |
| 2024-12-30 | 0.82 |
| 2024-12-27 | 0.83 |
| 2024-12-26 | 0.82 |
| 2024-12-24 | 0.79 |
| 2024-12-23 | 0.80 |
| 2024-12-20 | 0.82 |
| 2024-12-19 | 0.77 |
| 2024-12-18 | 0.79 |
| 2024-12-17 | 0.81 |
| 2024-12-16 | 0.84 |
| 2024-12-13 | 0.84 |
| 2024-12-12 | 0.83 |
| 2024-12-11 | 0.91 |
| 2024-12-10 | 0.95 |
| 2024-12-09 | 0.99 |
| 2024-12-06 | 1.01 |
| 2024-12-05 | 0.90 |
| 2024-12-04 | 0.85 |
| 2024-12-03 | 0.87 |
| 2024-12-02 | 0.90 |
| 2024-11-29 | 0.89 |
| 2024-11-27 | 0.79 |
| 2024-11-26 | 0.79 |
| 2024-11-25 | 0.82 |
| 2024-11-22 | 0.78 |
| 2024-11-21 | 0.81 |
| 2024-11-20 | 0.79 |
| 2024-11-19 | 0.86 |
| 2024-11-18 | 0.71 |
| 2024-11-15 | 0.75 |
| 2024-11-14 | 0.96 |
| 2024-11-13 | 1.06 |
| 2024-11-12 | 1.18 |
| 2024-11-11 | 0.80 |
| 2024-11-08 | 0.77 |
| 2024-11-07 | 0.81 |
| 2024-11-06 | 0.82 |
| 2024-11-05 | 0.82 |
| 2024-11-04 | 0.81 |
| 2024-11-01 | 0.80 |
| 2024-10-31 | 0.80 |
| 2024-10-30 | 0.83 |
| 2024-10-29 | 0.85 |
| 2024-10-28 | 0.84 |
| 2024-10-25 | 0.81 |
| 2024-10-24 | 0.84 |
| 2024-10-23 | 0.82 |
| 2024-10-22 | 0.84 |
| 2024-10-21 | 0.84 |
| 2024-10-18 | 0.85 |
| 2024-10-17 | 0.85 |
| 2024-10-16 | 0.92 |
| 2024-10-15 | 0.93 |
| 2024-10-14 | 1.00 |
| 2024-10-11 | 1.01 |
| 2024-10-10 | 1.04 |
| 2024-10-09 | 1.05 |
| 2024-10-08 | 1.02 |
| 2024-10-07 | 1.08 |
| 2024-10-04 | 1.02 |
| 2024-10-03 | 1.34 |
| 2024-10-02 | 1.34 |
| 2024-10-01 | 1.28 |
| 2024-09-30 | 1.20 |
| 2024-09-27 | 1.02 |
| 2024-09-26 | 1.10 |
| 2024-09-25 | 1.09 |
| 2024-09-24 | 1.17 |
| 2024-09-23 | 1.17 |
| 2024-09-20 | 1.17 |
| 2024-09-19 | 1.14 |
| 2024-09-18 | 1.16 |
| 2024-09-17 | 1.18 |
| 2024-09-16 | 1.18 |
| 2024-09-13 | 1.17 |
| 2024-09-12 | 1.12 |
| 2024-09-11 | 1.05 |
| 2024-09-10 | 1.04 |
| 2024-09-09 | 1.04 |
| 2024-09-06 | 1.05 |
| 2024-09-05 | 1.07 |
| 2024-09-04 | 1.05 |
| 2024-09-03 | 1.04 |
| 2024-08-30 | 1.09 |
| 2024-08-29 | 1.07 |
| 2024-08-28 | 1.07 |
| 2024-08-27 | 1.12 |
| 2024-08-26 | 1.15 |
| 2024-08-23 | 1.12 |
| 2024-08-22 | 1.07 |
| 2024-08-21 | 1.15 |
| 2024-08-20 | 1.23 |
| 2024-08-19 | 1.24 |
| 2024-08-16 | 1.19 |
| 2024-08-15 | 1.14 |
| 2024-08-14 | 1.16 |
| 2024-08-13 | 1.20 |
| 2024-08-12 | 1.26 |
| 2024-08-09 | 1.25 |
| 2024-08-08 | 1.29 |
| 2024-08-07 | 0.96 |
| 2024-08-06 | 0.95 |
| 2024-08-05 | 0.94 |
| 2024-08-02 | 0.98 |
| 2024-08-01 | 0.99 |
| 2024-07-31 | 1.03 |
| 2024-07-30 | 1.05 |
| 2024-07-29 | 1.13 |
| 2024-07-26 | 1.13 |
| 2024-07-25 | 1.15 |
| 2024-07-24 | 1.16 |
| 2024-07-23 | 1.19 |
| 2024-07-22 | 1.18 |
| 2024-07-19 | 1.14 |
| 2024-07-18 | 1.22 |
| 2024-07-17 | 1.32 |
| 2024-07-16 | 1.31 |
| 2024-07-15 | 1.25 |
| 2024-07-12 | 1.25 |
| 2024-07-11 | 1.21 |
| 2024-07-10 | 1.19 |
| 2024-07-09 | 1.15 |
| 2024-07-08 | 1.10 |
| 2024-07-05 | 1.10 |
| 2024-07-03 | 1.10 |
| 2024-07-02 | 1.01 |
| 2024-07-01 | 0.97 |
| 2024-06-28 | 1.01 |
| 2024-06-27 | 1.09 |
| 2024-06-26 | 1.04 |
| 2024-06-25 | 1.14 |
| 2024-06-24 | 1.13 |
| 2024-06-21 | 1.09 |
| 2024-06-20 | 1.08 |
| 2024-06-18 | 1.05 |
| 2024-06-17 | 1.03 |
| 2024-06-14 | 1.02 |
| 2024-06-13 | 1.06 |
| 2024-06-12 | 1.06 |
| 2024-06-11 | 1.07 |
| 2024-06-10 | 1.04 |
| 2024-06-07 | 1.04 |
| 2024-06-06 | 1.08 |
| 2024-06-05 | 1.14 |
| 2024-06-04 | 1.16 |
| 2024-06-03 | 1.37 |
| 2024-05-31 | 1.40 |
| 2024-05-30 | 1.44 |
| 2024-05-29 | 0.78 |
| 2024-05-28 | 0.69 |
| 2024-05-24 | 0.65 |
| 2024-05-23 | 0.65 |
| 2024-05-22 | 0.67 |
| 2024-05-21 | 0.68 |
| 2024-05-20 | 0.70 |
| 2024-05-17 | 0.75 |
| 2024-05-16 | 0.76 |
| 2024-05-15 | 0.75 |
| 2024-05-14 | 0.78 |
| 2024-05-13 | 0.67 |
| 2024-05-10 | 0.63 |
| 2024-05-09 | 0.65 |
| 2024-05-08 | 0.62 |
| 2024-05-07 | 0.63 |
| 2024-05-06 | 0.62 |
| 2024-05-03 | 0.64 |
| 2024-05-02 | 0.64 |
| 2024-05-01 | 0.64 |
| 2024-04-30 | 0.64 |
| 2024-04-29 | 0.66 |
| 2024-04-26 | 0.59 |
| 2024-04-25 | 0.59 |
| 2024-04-24 | 0.60 |
| 2024-04-23 | 0.63 |
Showing the most recent 260 of 936 data points. The chart above shows the full history.
Related Metrics
About 23andMe Holding Co.
23andMe Holding Co. is a prominent direct-to-consumer genetic testing firm, structured around two primary business units: Consumer & Research Services and Therapeutics. Through its Consumer & Research Services division, the company provides individuals with a comprehensive suite of genetic reports, derived from a simple saliva sample collected via their proprietary kit. These reports offer insights into customers' genetic ancestral origins, predispositions to certain personal health risks, the likelihood of being a carrier for rare conditions that could be passed to offspring, and how their genetic makeup might influence responses to various medications. The Therapeutics segment is dedicated to pharmaceutical research and development, focusing on the discovery and advancement of novel treatments aimed at improving patient well-being across diverse medical fields, including oncology, respiratory, and cardiovascular diseases. This segment also engages in the out-licensing of intellectual property associated with identified drug targets that are progressing through clinical development. 23andMe maintains a strategic partnership with GlaxoSmithKline Intellectual Property (No.3) Limited, leveraging genetic insights to validate, develop, and ultimately commercialize new pharmaceutical products. Established in 2006, the company's corporate headquarters are situated in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Joseph Selsavage